1 to 10 of 90 literature results

• International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations.

  An international interlaboratory proficiency testing program for the measurement of antifungal drugs was initiated in 2007. This first round was limit…

  Authors: Roger J M Brüggemann, Daan J Touw, Rob E Aarnoutse, Paul E Verweij, David M Burger

  Source: Antimicrobial agents and chemotherapy. 2009 Jan

  View Free Full Text

• Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.

  BACKGROUND: Co1nflicting data exist regarding the effect of efavirenz (EFV) plasma concentrations on central nervous system (CNS) toxicity. We aimed t…

  Authors: Matthijs van Luin, Wendy P Bannister, Amanda Mocroft, Peter Reiss, Giovanni Di Perri, Gilles Peytavin, José Molto, Anders Karlson, Antonella Castagna, Marek Beniowski,…

  Source: Antiviral therapy. 2009

  View Full Text

• Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily.

  BACKGROUND: Recently, a new tablet formulation of the widely used HIV protease inhibitor lopinavir/ritonavir was licensed. Here, we present a pilot st…

  Authors: Michiel van der Flier, Gwenda Verweel, Linda C van der Knaap, Petronette van Jaarsveld, Gert-Jan Driessen, Manon van der Lee, Nico G Hartwig, David M Burger

  Source: Antiviral therapy. 2008

  View Full Text

• Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.

  BACKGROUND: The tuberculosis (TB) mortality rate of registered TB patients in Malawi is 23%, and 59% of the deaths occur in the first 2 months of trea…

  Authors: Joep J G van Oosterhout, Johnstone J Kumwenda, Michael Beadsworth, Gabriel Mateyu, Temba Longwe, David M Burger, Eduard E Zijlstra

  Source: Antiviral therapy. 2007

  View Full Text

• Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.

  BACKGROUND: The pathogenesis of metabolic disturbances in treated HIV infection is incompletely understood. METHODS: Relationships between fasted meta…

  Authors: Reshma S Autar, Mark A Boyd, Ferdinand W M N Wit, Kiat Ruxrungthams, Jongkol Sankote, Joep Lange, David A Cooper, Praphan Phanuphak, David M Burger, Peter Reiss

  Source: Antiviral therapy. 2007

  View Full Text

• Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.

  BACKGROUND: Lopinavir/ritonavir (LPV/r) has been licensed for the treatment of HIV-infected children >6 months in the US and >2 years in the EU. Limit…

  Authors: Gwenda Verweel, David M Burger, Nancy L Sheehan, Alina S Bergshoeff, Adilia Warris, Linda C van der Knaap, Gertjan Driessen, Ronald de Groot, Nico G Hartwig

  Source: Antiviral therapy. 2007

  View Full Text

• Role of the inhibitory quotient in HIV therapy.

  A systemic review is presented of all studies that have evaluated the inhibitory quotient (IQ). The IQ is defined as the ratio between (trough) drug c…

  Authors: Jolando G M Hoefnagel, Peter P Koopmans, David M Burger, Rob Schuurman, Jochem M D Galama

  Source: Antiviral therapy. 2005

  View Full Text

• Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR).

  OBJECTIVE: To assess the pharmacokinetics and tolerability of reduced dosages of twice daily indinavir (IDV) boosted by low-dose ritonavir (RTV) in he…

  Authors: Jan-Christian Wasmuth, Charles J L la Porte, Katrin Schneider, David M Burger, Juergen K Rockstroh

  Source: Antiviral therapy. 2004 Apr

  View Full Text

• Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).

  INTRODUCTION: The use of HIV protease inhibitors (PIs) in a ritonavir (RTV)-boosted form is now common. However, randomized data comparing boosted wit…

  Authors: Mark A Boyd, Preeyaporn Srasuebkul, Mana Khongphattanayothin, Kiat Ruxrungtham, Elly A M Hassink, Christopher J Duncombe, Sasiwimol Ubolyam, David M Burger, Peter Reiss, Michael Stek,…

  Source: Antiviral therapy. 2006

  View Full Text

• Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.

  Human immunodeficiency virus-infected patients have an increased risk for depression. Despite the high potential for drug-drug interactions, limited d…

  Authors: Manon J van der Lee, Audrey A M Blenke, Gerard A Rongen, Corrien P W G M Verwey-van Wissen, Peter P Koopmans, Cristina Pharo, David M Burger

  Source: Antimicrobial agents and chemotherapy. 2007 Nov

  View Free Full Text